Neuroendocrine differentiation of prostate cancer

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway

(2012) Hongbing Chen et al.   ENDOCRINE-RELATED CANCER

Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer

(2012) Himisha Beltran et al.   JOURNAL OF CLINICAL ONCOLOGY

From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer

(2012) Anna V Lapuk et al.   JOURNAL OF PATHOLOGY

PC3 is a cell line characteristic of prostatic small cell carcinoma

(2011) Sheng Tai et al.   PROSTATE

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

Small Cell Carcinoma of the Prostate

(2009) Wenle Wang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Targeted Knockdown of EGR-1 Inhibits IL-8 Production and IL-8-mediated Invasion of Prostate Cancer Cells through Suppressing EGR-1/NF-κB Synergy

(2009) Jiajia Ma et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

SharedTP53gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate

(2009) Donna E. Hansel et al.   PROSTATE

Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence

(2008) Juan C. Acosta et al.   CELL